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Intradermal Injection of Bone Marrow Mesenchymal Stromal Cells Corrects Recessive Dystrophic Epidermolysis Bullosa in a Xenograft Model
Journal of Investigative Dermatology (2018 doi: 10.1016 /j.jid.2018 TO THE EDITOR Recessive dystrophic epidermolysis bullosa (RDEB) is caused by loss-offunction mutations in COL7A1 encoding type VII collagen (C7) that forms anchoring fibrils (AFs), structures essential for dermal-epidermal adherence (Uitto et al., 2017) . Patients with RDEB suffer from skin and mucosal blistering and develop severe complications including invasive squamous cell carcinoma, resulting in a poor prognosis (Guerra et al., 2017) . Different therapeutic strategies have been explored, including gene-, protein-, cell-based, and pharmacological therapies that have shown promising preclinical or transitory clinical benefits (Rashidghamat and McGrath, 2017) . To date, there is no specific treatment for RDEB.
Bone marrowemesenchymal stromal cells (BM-MSCs) have shown therapeutic potential for RDEB patients through BM transplantation and intradermal (ID) and intravenous injections (Conget et al., 2010; El-Darouti et al., 2016; Petrof et al., 2015; Tamai et al., 2011; Tolar et al., 2009; Wagner et al., 2010) .
Human bone marrowe mesenchymal stromal cells (hBMMSCs) form a heterogeneous cell population that can self-renew or differentiate into mesenchymal lineages (Caplan, 1991) . hBM-MSCs display properties that could potentially improve wound healing in RDEB: immunomodulation; anti-inflammatory, angiogenic, and antifibrotic properties; secretion of trophic factors; improvement of tissue repair; and the capacity to induce protein expression in the host tissues through a paracrine effect (Nuschke, 2014; Qi et al., 2014) .
Herein, we assessed the long-term capacity of hBM-MSCs to survive, produce, and deposit C7 at the dermalepidermal junction (DEJ) after ID injection into human RDEB skin equivalents (SEs) transplanted onto immune-deficient nude mice that reproduce the skin defect observed in RDEB (Titeux et al., 2010) .
Phenotypic analyses of hBM-MSCs from healthy donors showed that they were positive for well-established surface markers (CD105, CD90, CD73, CD29, and CD44) and negative for potential hematopoietic contaminants (HLA-DR and CD45) (see Supplementary Figure S1 online). The capacity of these hBM-MSCs to differentiate in vitro into osteoblasts, adipocytes, and chondrocytes was previously shown (Peltzer et al., 2015) .
Then, we compared COL7A1 expression in hBM-MSCs from several donors cultured with 5% human platelet lysate or 10% fetal calf serum (see Supplementary Figure S2a and b online). C7 expression by hBM-MSCs from donor 1 was similar to human healthy fibroblasts when grown in human platelet lysate, whereas hBM-MSCs from other donors showed lower amounts of C7 (see Supplementary Figure S2c , d, and e).
We next tested the capacity of hBMMSCs to synthesize C7 able to form AF structures in vivo in a xenograft model. We ID injected hBM-MSCs beneath RDEB SE completely devoid of C7 expression (see Supplementary Figure S3 online), thus excluding any possible paracrine effect of hBM-MSCs on hRDEB fibroblasts and/or keratinocytes, leading to increased production of endogenous mutant C7. The dose of 2 Â 10 6 of hBM-MSC was chosen based on a previous preclinical study (Kuhl et al., 2015) . We collected SE samples from the injected area at 1, 2, 4, and 6 months after treatment. Immunofluorescence staining of SE sections showed linear staining of human C7 (see Supplementary Figure S4 online) along the DEJ up to 6 months in healthy SEs and in hBM-MSCeinjected RDEB SEs, whereas vehicle-injected RDEB SEs showed no detectable C7 staining ( Figure 1a ). Semiquantitative analysis of C7 fluorescence signal showed that hBM-MSC injection induced a significant increase in C7 deposition (up to 30%e40% of the level of healthy control SE) compared with vehicle-injected RDEB SE (Figure 1c ), which is considered to be sufficient to prevent loss of dermal-epidermal adhesion (Fritsch et al., 2008) . Similar results were observed after injection of hBM-MSCs from donor 5 in RDEB SEs (see Supplementary Figure S5 online).
Transmission electron microscopy showed the presence of AFs up to 6 months with typical loop-shaped structures inserted into the lamina densa in ID hBM-MSCeinjected RDEB SEs and in healthy SEs, but no AF structures were found in vehicleinjected RDEB SEs (Figure 1b) . Morphometric analyses showed a significant increase of AF number, especially at 2 months, a time when AF density was similar to healthy SE (95% of healthy control) ( Figure 1d , and see Supplementary Figure S6 online).
The fate of injected hBM-MSCs in the RDEB SEs was assessed by fluorescent in situ hybridization using probes specific for human X and Y chromosomes (see Supplementary Figure S7 Nonparametric Mann-Whitney test. *P < 0.05, **P < 0.01. n ! 3 mice for each time point. AF, anchoring fibril; C7, collagen type VII; hBM-MSC, human bone marrow mesenchymal stromal cell; ID, intradermal; ns, not significant; RDEB, recessive dystrophic epidermolysis bullosa; SE, skin equivalent; TEM, transmission electron microscopy.
human male donor. Fluorescent in situ hybridization analysis showed the presence of human X-Y chromosomee positive cells in the dermis at 1, 2, and 4 months after injection. No X-Y chromosomeepositive cells were found in the dermis of RDEB SE 6 months after injection (Figure 2a) . Therefore, injected hBM-MSCs were observed in the dermis of RDEB SEs up to 4 months after injection, but their number clearly diminished over time (Figure 2b ). Immunofluorescence staining of the active cleaved caspase-3 showed that hBM-MSCeinjected RDEB SEs displayed numerous apoptotic cells in the dermis from 2 to 4 months (Figure 2c ), whereas no cells were detected in vehicleinjected RDEB SEs. The number of apoptotic cells expanded up to 4 months and decreased at 6 months, suggesting that most of the injected hBM-MSCs underwent apoptosis between 2 and 4 months after injection (Figure 2d ). Previous RDEB studies using hBMMSCs showed restoration of C7 at the DEJ for at least 12 weeks, although C7 production decreased over time (Conget et al., 2010; Kuhl et al., 2015) . We show a longer effect of hBM-MSCs on C7 production and AF formation (up to 6 months). This is likely due to the extended survival time of injected hBMMSCs (up to 4 months) compared with the 28 days previously reported (Kuhl et al., 2015) , attributable to the lack of immune rejection in our immunedeficient model.
Localized ID injections and the survival of injected hBM-MSCs may represent limitations to treating all symptoms of RDEB. However, ID injections could be repeated over time to sustain clinical benefit in RDEB patients. In addition, systemic delivery of hBM-MSCs could be envisaged, although the extent to which systemic delivery of hBM-MSCs allows engraftment of injected cells in the skin and restoration of C7 is not known (Webber et al., 2017) . Therefore, if the treatment has to be repeated for a long period, the risk of allo-reactions to allogeneic hBM-MSCs through the semidirect allorecognition pathway (Alegre et al., 2016) may impair the efficacy of these approaches. An alternative would be to use gene-corrected autologous hBM-MSCs to improve persistence of injected cells and to allow repeated injections.
This study was conducted in accordance with ethical principles stated in the Declaration of Helsinki. Patient consent for experiments was not required, because the French law considers human tissue left over from surgery as discarded material. The mice experiments were performed in compliance with guidelines for animal experiments in France and were approved by the local animal research ethics committee.
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